第18版WHO基本药物目录对我国基本药物及社保药物目录的借鉴意义

Reference significance of 18th National essential medicine List of WHO on the essential medicine list, National insurance medicine list of China

目的:参照《世界卫生组织(WHO)基本药物标准清单》第18版(WHO-EML),比较我国《国家基本药物目录》2012年版(C-EML)与我国《国家基本医疗保险、工伤保险和生育保险药品目录》2009年版(EI-ML)的与其异同,结合目前临床使用情况,为调整我国新的C-EML和EI-ML提供借鉴基础。方法:比较分析WHO-EML、C-EML及EI-ML在药物分类、药品品种及药物剂型等方面的异同。结果:与WHO-EML比较,C-EML和EI-ML药品类别和口服液体剂型有缺失;C-EML、EI-ML与WHO-EML药品品种的重合率分别为28.6%、42.6%;3个目录中,构成比位居前三的药品类别相同。结论:WHO-EML药品种类及品种较我国目录丰富,应结合我国的实际情况,科学合理地补充并修订我国基本药物和社保药物目录。

Objective： With the reference of thel8th Edition of National Essential Medicine List of WHO （WHO-EML）, Essential Medicine List of China （C-EML）（ 2012 version） and National Insurance Medicine List of China （2009 version） （EI-ML） were compared in order to provide a scientific evidence for adjustment of the new C-EML and EI-ML of China combined with the use of current clinical. Methods： Comparative analysis on the difference between WHO-EML, C-EML and EI-ML was conducted in the classification of drugs, drug varieties, and the differences of drug dosage forms. Results： Compared with WHO-EML, there were some missing medicine category and oral liquid dosage forms in C-EML and EI-ML. Alignment rates of medicines for C-EML, EI-ML were 28.6% and 42.6% respectively compared to WHO-EML. Among three lists, the ratios of top three medicine category were the same. Conclusion： The medicines categories and varieties of WHO-EML are richer than the lists of China. C-EML and EI-ML need further revision and scientific supplement combined with China＇s actual situation.